Dr. Robin J. Steele, J.D. LL.M serves as Independent Director of the company. Ms. Steele served as an advisor to Daré Operations since its inception in 2015. Ms. Steele previously served as Senior Vice President, General Counsel and Secretary of InterMune, Inc., a publicly traded biopharmaceutical company, from 2004 to 2014. Prior to her tenure with InterMune, Ms. Steele served as Vice President of Legal Affairs for North America for Elan Pharmaceuticals, a publicly traded pharmaceutical company, from 1998 to 2003. Ms. Steele currently serves on the board of directors of Alveo Technologies Inc., a privately held medical diagnostics company. Ms. Steele has previously served as a member of the board of directors of Alios Biopharma and Targanta Therapeutics, both of which were biotechnology companies focused on the research and development of therapeutic compounds prior to their respective acquisitions. Ms. Steele received a B.A. from the University of Colorado, a J.D. from the University of California, Hastings College of the Law, and an LL.M. in Taxation from New York University School of Law. The Board of Directors believes that Ms. Steele is qualified to serve on the Company’s Board of Directors due to her expertise in legal matters, her prior experience as general counsel of a public company and her involvement with a number of private biotechnology companies.
Robin Steele is 58, he's been the Independent Director of Dare Bioscience Inc since 2017. There are 6 older and 5 younger executives at Dare Bioscience Inc. The oldest executive at Dare Bioscience Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
Robin's mailing address filed with the SEC is 3655 NOBEL DRIVE SUITE 260, , SAN DIEGO, CA, 92122.
Over the last 7 years, insiders at Dare Bioscience Inc have traded over $0 worth of Dare Bioscience Inc stock and bought 594,545 units worth $703,000 . The most active insiders traders include William H Rastetter, Roger Hawley und Cheryl R Blanchard. On average, Dare Bioscience Inc executives and independent directors trade stock every 152 days with the average trade being worth of $969,110. The most recent stock trade was executed by Roger Hawley on 11 April 2019, trading 454,545 units of DARE stock currently worth $500,000.
daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.
Dare Bioscience Inc executives and other stock owners filed with the SEC include: